
The Revolution to Change Chronic Disease Management and Save Lives is Here

And that revolution is not more GLP-1s.
For decades, even the most highly trained medical doctors have been taught that the best we can do is manage the symptoms of chronic, progressive diseases to slow their progression…
1. Type 2 Diabetes
2. Hypertension
3. Cardiovascular disease
4. Kidney Disease
5. Fatty Liver Disease
6. Obesity
…with an ever increasing dose of symptom lowering medications, such as insulin for diabetes.
All this approach has got us is 93% of American Adults with one or more of these chronic disease symptoms, declining life expectancy, and trillions of dollars directly attributable to annual health care costs. The numbers are only getting worse.
The bad news is not even news anymore - this status quo approach is not working and we had our facts wrong. Good news - we now know why and we know a better way.
After treating 200,000+ Americans, following our patients for up to a decade and collecting hundreds of millions of patient data points in our Virta Health care, we can now confidently state the following, which I believe will be the basis for a revolution in Metabolic Disease care:
- Metabolic Disease is one condition, manifesting itself with several “chronic disease” symptoms
- The primary driver of Metabolic Disease is nutrition. And food can’t be fixed with drugs. It can be fixed with better, individualized nutrition
- Metabolic disease can be systematically and sustainably reversed at the root cause level, reversing all “chronic diseases” at the same time
- Reversing metabolic disease with nutrition doesn’t just improve lives, but it saves lives and reduces heart attacks and strokes better than any drug out there
The future of metabolic disease care is reversal, not life-long management of many chronic conditions with drugs. And best of all, that future is already here.
We know this, because today we can share that the provider-led and individualized Virta nutrition program has achieved the following outcomes (*denotes published, peer-reviewed results):
- *60% T2D reversal rate with 13% sustained weight loss
- *11% reduction of hypertension medication
- 56% reduced risk of heart attack, stroke, or death (more than GLP-1s)
- Reduce new chronic kidney disease diagnoses by 33%
- *60% decrease in liver fat score
- 53-64% reduction in all-cause mortality - more than GLP-1’s
I am confident in saying the future of metabolic disease care is reversing the root cause with nutrition. It works in N=1, at scale and across all races, ethnicities and socio-economic groups(footnote).
Skeptics might still ask, but are the results sustainable? Maybe it’s just for the 1%?
We now know Virta can work for anyone on a population level and twice as many people stick to our virtually delivered individualized programs than take GLP-1’s at one year; and we’ve followed many of our patients for more than 5 years. Virta works.
But this is just Day One for us at Virta. We believe there are more metabolic disease related conditions that we can reverse or improve and we will be sharing more data in the future.
We’ve now proven that reversal with nutrition is possible at scale. Now we still need to make it the new norm of chronic disease care. Let’s replace today’s default of lifelong medication and slow decline with a new standard, one built on evidence, optimism, and food that heals.
Please read our inaugural Metabolic Disease report. Share it with your clinician, a colleague, or a friend. Help spark a movement towards Metabolic Disease Reversal. This isn't a theory or hope anymore. It’s happening.
Thank you.
Sami Inkinen
CEO & Co-Founder
This blog is intended for informational purposes only and is not meant to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or any advice relating to your health. View full disclaimer
Are you living with type 2 diabetes, prediabetes, or unwanted weight?
https://pmc.ncbi.nlm.nih.gov/articles/PMC6104272/
https://www.mdpi.com/2072-6643/13/3/749
https://cardiab.biomedcentral.com/articles/10.1186/s12933-018-0698-8
https://www.medrxiv.org/content/10.1101/2025.10.27.25338916v1
https://www.medrxiv.org/content/10.1101/2025.10.17.25338238v1
https://bmjopen.bmj.com/content/9/2/e023597.long
https://www.medrxiv.org/content/10.1101/2025.10.27.25338916v1



.jpg)


